Shareholder Class Action

Directors are selling Zeltiq Aesthetics, a medical tech company, too cheaply through an unfair process to Allergan, for $56.50 a share or $2.5 billion, shareholders say in Federal Court.

SAN FRANCISCO – Directors are selling Zeltiq Aesthetics, a medical tech company, too cheaply through an unfair process to Allergan, for $56.50 a share or $2.5 billion, shareholders say in Federal Court.